Earticle

초록

영어

Objective: This study was designed to compare pegfilgrastim and filgrastim in diffuse large B-cell lymphoma (DLBCL) patients treated with a rituximab with cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (R-CHOP) regimen in terms of clinical efficacy and cost-effectiveness. Method: Clinical efficacy was measured by trough level of absolute neutrophil count (ANC), days of ANC under 50% of baseline value, days of ANC under 90% of baseline value, duration of ANC recovery to baseline value, days of ANC less than 0.5 × 109 cells/L, and difference of peak and trough level of ANC during 1 cycle of R-CHOP regimen. To evaluate cost-effectiveness, total prices of used filgrastim and pegfilgrastim within 1 cycle of R-CHOP were analyzed. Results: In terms of clinical efficacy, trough level of ANC and days to ANC recovery showed statistical significance. The median trough levels of ANC with administration of filgrastim and pegfilgrastim were 0.18 and 1.94 (p = 0.021), respectively, and the median durations of ANC recovery to baseline value were 5.5 days and 2 days (p = 0.023), respectively. For the median days of ANC under 50% of baseline value, days of ANC under 90% of baseline value, days of ANC less than 0.5 × 109 cells/L, and difference of peak and trough level of ANC during 1 cycle of R-CHOP, the pegfilgrastim group performed better than the filgrastim group. However the difference was not statistically significant. In terms of overall expense during 1 cycle of R-CHOP, pegfilgrastim is about 3.43 times more expensive than filgrastim. Conclusion: Pegfilgrastim is more efficient than filgrastim in terms of clinical efficacy. In terms of prices, pegfilgrastim is more expensive than filgrastim for patients, but it is more convenient in clinical use. Therefore, pegfilgrastim should be the preferred choice of G-CSF for neutropenic patients. Further comparative study of pegfilgrastim and filgrastim is needed.

목차

ABSTRACT
 연구 방법
  대상 환자 및 제품
  자료의 수집과 분석
  통계분석
 연구 결과
  대상 환자의 특성
 혈중 ANC수치 비교
  최저치 비교를 통한 호중구 감소증 정도 평가
  중증의 호중구 감소증 기간 평가
  경증의 호중구 감소증 기간 평가
  ANC 최저치로부터 기저치로 회복되기까지의 일수 평가
  절대값 ANC 수치 0.5 이하인 기간 평가
  최대값과 최소값의 차이
  약가비교
 고찰
 결론
 감사의 말씀
 참고문헌

키워드

저자

• 정희원 [ Hee Won Jung | 숙명여자대학교 임상약학대학원, 삼성서울병원 약제부 ]
• 김정미 [ Jeong Mee Kim | 삼성서울병원 약제부 ]
• 민명숙 [ Myung Sook Min | 삼성서울병원 약제부 ]
• 이영미 [ Young Mee Lee | 삼성서울병원 약제부 ]
• 방준석 [ Joon Seok Bang | 숙명여자대학교 임상약학대학원 ] Corresponding author

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국임상약학회지 [Korean Journal of Clinical Pharmacy]

• 간기

  계간

• pISSN

  1226-6051

• 수록기간

  1991~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 518 DDC 615